A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
Clinical trial NCT04355520 · UNKNOWN
Trial details
- NCT number
- NCT04355520
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-01
- Primary completion
- 2021-06-01
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.